Improved anti-glioblastoma efficacy by IL-13Rα2 mediated copolymer nanoparticles loaded with paclitaxel

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Wang, Baoyan ^a,b   Lv, Lingyan ^a   Wang, Zhi ^a   Jiang, Yan ^a   Lv, Wei ^a   Liu, Xin ^a   Wang, Zhongyuan ^a   Zhao, Yue ^a   Xin, Hongliang ^a   Xu, Qunwei ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG CARRIER; INTERLEUKIN 13 RECEPTOR ALPHA2; NANOPARTICLE; PACLITAXEL;

ANIMAL; BAGG ALBINO MOUSE; BRAIN; BRAIN NEOPLASMS; DRUG SCREENING; GLIOBLASTOMA; INSTITUTE FOR CANCER RESEARCH MOUSE; MALE; METABOLISM; NUDE MOUSE; RAT; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; DRUG CARRIERS; GLIOBLASTOMA; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; MALE; MICE, INBRED BALB C; MICE, INBRED ICR; MICE, NUDE; NANOPARTICLES; PACLITAXEL; RATS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84947279586     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep16589     Document Type: Article

References (41)

1. Iacob, G. & Dinca, E. B. Current data and strategy in glioblastoma multiforme. J Med Life 2, 386-93 (2009).
2. Lawrence, R. N. William Pardridge discusses the lack of BBB research. Drug Discov Today 7, 223-26 (2002).
3. Pardridge, W. M. BBB-Genomics: creating new openings for brain-drug targeting. Drug Discov Today 6, 381-83 (2001).
4. Gupta, M. L., Bode, C. J. & Georg, G. I. & Himes, R. H. Understanding tubulin-Taxol interactions: mutations that impart Taxol binding to yeast tubulin. Proc Natl Acad Sci USA 100, 6394-97 (2003).
5. Prados, M. D. et al. Phase II study of paclitaxel in patients with recurrent malignant glioma. J Clin Oncol 14, 2316-21 (1996).
6. Chang, S. et al. A phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants: a north American brain tumor consortium report. Cancer 91, 417-22 (2001).
7. Maeda, H. et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65, 271-84 (2000).
8. Berzofsky, J. A. et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 113, 1515-25 (2004).
9. Ribas, A., Butterfield, L. H. & Glaspy, J. A. & Economou, J. S. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 21, 2415-32 (2003).
10. Madhankumar, A. B. et al. Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor model. Mol Cancer Ther 8, 648-54 (2009).
11. Kawakami, K., Taguchi, J. & Murata, T. & Puri, R. K. The interleukin-13 receptor α 2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway. Blood 97, 2673-79 (2001).
12. Kioi, M. et al. Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy. Technol Cancer Res Treat 5, 239-50 (2006).
13. Debinski, W. et al. Novel anti-brain tumor cytotoxins specific for cancer cells. Nat Biotechnol 16, 449-53 (1998).
14. Husain, S. R. & Puri, R. K. Interleukin-13 fusion cytotoxin as a potent targeted drug for AIDS-Kaposi's sarcoma xenograft. Blood 95, 3506-13 (2000).
15. Bera, T. K., Viner, E. B. & Pastan, I. Pharmacokinetics and antitumor activity of a bivalent disulphide-stabilized Fv immunotoxin with improved antigen binding to erbB2. Cancer Res 59, 4018-22 (1999).
16. Husain, S. R., Joshi, B. H. & Puri, R. K. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int J Cancer 92, 168-75 (2001).
17. Wang, B. et al. Nanoparticles functionalized with Pep-1 as potential glioma targeting delivery system via interleukin 13 receptor α2-mediated endocytosis. Biomaterials 35, 5897-907 (2014).
18. Vehlow, A. & Cordes, N. Invasion as target for therapy of glioblastoma multiforme. Biochim Biophys Acta 1836, 236-44 (2013).
19. Juratli, T. A., Schackert, G. & Krex, D. Current status of local therapy in malignant gliomas-a clinical review of three selected approaches. Pharmacol Ther 139, 341-58 (2013).
20. Chen, Y. & Liu, L. Modern methods for delivery of drugs across the blood-brain barrier. Adv Drug Deliv Rev 64, 640-65 (2012).
21. Régina, A. et al. Antitumor activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol 155, 185-97 (2008).
22. Thomas, F. C. et al. Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm Res 26, 2486-94 (2009).
23. Wen, Z. et al. Odorranalectin-conjugated nanoparticles: Preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration. J Control Release 151, 131-38 (2011).
24. Hu, Q. et al. Glioma therapy using tumor homing and penetrating peptidefunctionalized PEG-PLA nanoparticles loaded with paclitaxel. Biomaterials 34, 5640-50(2013).
25. Lin, J. et al. Folic acid-Pluronic F127 magnetic nanoparticle clusters for combined targeting, diagnosis, and therapy applications. Biomaterials 30, 5114-24 (2009).
26. Yan, Z. et al. LyP-1-conjugated PEGylated liposomes: A carrier system for targeted therapy of lymphatic metastatic tumor. J Control Release 157, 118-25 (2012).
27. Bozinov, O. et al. Decreasing expression of the interleukin-13 receptor IL-13Ralpha2 in treated recurrent malignant gliomas. Neurol Med Chir 50, 617-21 (2010).
28. Gao, H. et al. RGD and interleukin-13 peptide functionalized nanoparticles for enhanced glioblastoma cells and neovasculature dual targeting delivery and elevated tumor penetration. Mol Pharm 11, 1042-52(2014).
29. Mintz, A. et al. IL-13Ralphα 2 is a glioma-restricted receptor for interleukin-13. Neoplasia 4, 388-99 (2002).
30. Pandya, H. et al. An interleukin 13 receptor a 2-specific peptide homes to human Glioblastoma multiforme xenografts. Neuro Oncol 14, 6-18 (2012).
31. Torchilin, V. P. Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol 197, 3-53 (2010).
32. Shyh-Dar L. & Leaf H. Pharmacokinetics and biodistribution of nanoparticles. Mol. Pharmaceutics 5, 496-504 (2008).
33. Hongliang X. et al. Angiopep-conjugated poly(ethylene glycol)-co-poly(epsilon-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. Biomaterials 32, 4293-305(2011).
34. Xinyi J. et al. PEGylated poly(trimethylene carbonate) nanoparticles loaded with paclitaxel for the treatment of advanced glioma: in vitro and in vivo evaluation. Int J Pharm 420, 385-94(2011).
35. Balda M. S. et al. Tight junctions and the regulation of gene expression. Biochim Biophys Acta 1788, 761-67 (2009).
36. Kniesel U. et al. Tight junctions of the blood-brain barrier. Cell. Mol. Neurobiol 20, 57-76(2000).
37. Huber J. D. et al. Molecular Physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci 24, 719-25 (2001).
38. Li, S. & Huang, L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 5, 496-504 (2008).
39. Xin, H. et al. Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles as dual-targeted drug delivery system for brain glioma. Biomaterials 32, 4293-305 (2011).
40. Wu, J. et al. Polyethylene glycol-polylactic acid nanoparticles modified with cysteine-arginine-glutamic acid-lysine-alanine fibrinhoming peptide for glioblastoma therapy by enhanced retention effect. International Journal of Nanomedicine 9, 5261-71 (2014).
41. Zhang, X. et al. Follicle-stimulating hormone peptide can facilitate paclitaxel nanoparticles to target ovarian carcinoma in vivo. Cancer Res 69, 6506-14 (2009).